The suppressive tumor microenvironment: a challenge in cancer immunotherapy

Mol Pharm. 2011 Jun 6;8(3):635-41. doi: 10.1021/mp1004228. Epub 2011 May 5.

Abstract

In this review, we introduce the changing public perception of vaccines and immunotherapy in cancer treatments. We discuss the roles that different immunosuppressive cells play in the tumor microenvironment. Tumor associated macrophages (TAMs) and M1 and M2 macrophage phenotypes are discussed in depth. Additionally, the role that myeloid derived suppressor cells (MDSC) and T regulatory cells (Tregs) play in the tumor microenvironment is addressed. Highlighted are examples of therapies used against each suppressive cell type, which vary from the hypothetical to the ineffective; the inefficient to the successful. A variety of treatments have been tried to combat this fundamental problem, indeed the cause that allows cancerous mutated cells to survive, multiply and overtake the body. Efficient methods to disable each particular suppressive type of cell have been introduced; this review summarizes the discussion with a table to guide future development. We see gene therapy as the most innovative and flexible method to lead the charge to specifically modifying the tumor microenvironment.

Publication types

  • Review

MeSH terms

  • Animals
  • Humans
  • Immunotherapy / methods*
  • Macrophages / immunology*
  • Models, Biological
  • Neoplasms / immunology*
  • Neoplasms / therapy*
  • T-Lymphocytes, Regulatory / immunology